Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Holding LGND?
Track your performance easily
LGND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$67.72 - $129.90
Previous CloseN/A
Volume21.09K
Average Volume (3M)121.36K
Market Cap
$2.10B
Enterprise Value$1.63B
Total Cash (Recent Filing)$141.05M
Total Debt (Recent Filing)$29.56M
Price to Earnings (P/E)44.5
Beta1.35
Next Earnings
Feb 06, 2025EPS Estimate
1.19Last Dividend Ex-Date
Nov 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)2.51
Shares Outstanding18,895,372
10 Day Avg. Volume93,713
30 Day Avg. Volume121,365
Standard Deviation0.17
R-Squared0.11
Alpha0.00791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.77
Price to Cash Flow (P/CF)14.40
P/FCF Ratio14.60
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue10.70
Enterprise Value/Gross Profit13.50
Enterprise Value/Ebitda23.69
Forecast
1Y Price Target
$149.20Price Target Upside33.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ligand Pharma News
Ownership Overview
2.49% Insiders
37.69% Mutual Funds
0.58% Other Institutional Investors
32.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $67.72 and its highest was $129.90 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $2.10B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Feb 06, 2025 which is in 16 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Nov 07, 2024. The company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.347 by $0.493.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $30.012 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.19.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 18,895,372 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $1.84 in its last earnings report, beating expectations of $1.347. Following the earnings report the stock price went up 11.121%.
Which hedge fund is a major shareholder of Ligand Pharma?
Among the largest hedge funds holding Ligand Pharma’s share is Private Capital Management, LLC. It holds Ligand Pharma’s shares valued at 13M.
---
Ligand Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$149.20 (33.35% Upside)
$149.20 (33.35% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 82.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $542.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.90%
12-Months-Change
Fundamentals
Return on Equity
6.00%
Trailing 12-Months
Asset Growth
24.13%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
---
LGND Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter for Ligand with significant revenue growth and successful product launches. Financial guidance was raised, indicating confidence in continued momentum. However, there were some challenges, including a decline in Captisol sales and increased operating expenses. Overall, the positives in revenue growth, product launches, and strong financial outlook significantly outweighed the negatives.Read More>---
LGND Stock 12 Month Forecast
Average Price Target
$149.20
▲(33.35% Upside)
Technical Analysis
Best Analysts Covering LGND
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+10.51%
assigned a buy rating 8 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +10.51% per trade.
---